AR and prostate carcinoma: A particularly striking scenario is the bone metastatic niche in which prostate cancer cells, either lacking the AR or with this receptor inactivated by therapy, produce and secrete IL-1β, which is normally repressed by the binding of the AR to at least one ARE half-site near the IL-1β promoter.